Stay updated on Lenvatinib and Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in HCC Clinical Trial page
- Check7 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a newer version of the document label on the page. It reflects an update to the page's versioning rather than substantive content changes.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe revision label has been updated from Revision: v3.5.3 to Revision: v3.5.4. This reflects a newer revision of the document in the revision history.SummaryDifference0.0%

- Check35 days agoChange DetectedTaoyuan District, Taiwan, 333 was removed and Taoyuan, Taiwan, 333 was added in the Locations section, reflecting a corrected city designation for the recruitment site.SummaryDifference0.0%

- Check43 days agoChange DetectedThe page's revision label has been updated from v3.5.2 to v3.5.3. This reflects a minor update to the page's metadata or documentation.SummaryDifference0.0%

- Check57 days agoChange DetectedAdded revision note: v3.5.2; removed revision: v3.5.0.SummaryDifference0.0%

- Check64 days agoChange Detected- Padua, Italy, 35128 was replaced by Padova, Italy, 35128 in the locations list.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib and Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.